163 related articles for article (PubMed ID: 24904105)
21. Low-level expression of ETV6/TEL in patients with Myelodysplastic syndrome.
Yamagata T; Nakamura Y; Mitani K
Int J Hematol; 2007 Oct; 86(3):282-5. PubMed ID: 17988997
[No Abstract] [Full Text] [Related]
22. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.
Sallman DA; Komrokji R; Cluzeau T; Vaupel C; Al Ali NH; Lancet J; Hall J; List A; Padron E; Song J
Blood Cancer J; 2017 Nov; 7(12):633. PubMed ID: 29176559
[No Abstract] [Full Text] [Related]
23. Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Weeks LD; Marinac CR; Redd R; Abel G; Lin A; Agrawal M; Stone RM; Schrag D; Ebert BL
Blood; 2022 Feb; 139(8):1246-1250. PubMed ID: 34875037
[No Abstract] [Full Text] [Related]
24. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
25. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
26. The myelodysplastic/myeloproliferative disorders: the interface.
Bennett JM
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1095-100, v. PubMed ID: 14560776
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
28. ETV6: a versatile player in leukemogenesis.
Bohlander SK
Semin Cancer Biol; 2005 Jun; 15(3):162-74. PubMed ID: 15826831
[TBL] [Abstract][Full Text] [Related]
29. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.
Zhao LP; Boy M; Azoulay C; Clappier E; Sébert M; Amable L; Klibi J; Benlagha K; Espéli M; Balabanian K; Preudhomme C; Marceau-Renaut A; Benajiba L; Itzykson R; Mekinian A; Fain O; Toubert A; Fenaux P; Dulphy N; Adès L
Leukemia; 2021 Sep; 35(9):2720-2724. PubMed ID: 33623140
[No Abstract] [Full Text] [Related]
30. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.
Zhao LP; Schell B; Sébert M; Kim R; Lemaire P; Boy M; Mathis S; Larcher L; Chauvel C; Dhouaieb MB; Bisio V; Preudhomme C; Marceau-Renaut A; Itzykson R; Mekinian A; Fain O; Toubert A; Fenaux P; Dulphy N; Clappier E; Adès L
Leukemia; 2021 Sep; 35(9):2731-2733. PubMed ID: 34344988
[No Abstract] [Full Text] [Related]
31. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
32. Loss of the tumor suppressor BAP1 causes myeloid transformation.
Dey A; Seshasayee D; Noubade R; French DM; Liu J; Chaurushiya MS; Kirkpatrick DS; Pham VC; Lill JR; Bakalarski CE; Wu J; Phu L; Katavolos P; LaFave LM; Abdel-Wahab O; Modrusan Z; Seshagiri S; Dong K; Lin Z; Balazs M; Suriben R; Newton K; Hymowitz S; Garcia-Manero G; Martin F; Levine RL; Dixit VM
Science; 2012 Sep; 337(6101):1541-6. PubMed ID: 22878500
[TBL] [Abstract][Full Text] [Related]
33. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Chesnais V; Kosmider O; Damm F; Itzykson R; Bernard OA; Solary E; Fontenay M
Oncotarget; 2012 Nov; 3(11):1284-93. PubMed ID: 23327988
[TBL] [Abstract][Full Text] [Related]
34. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
[TBL] [Abstract][Full Text] [Related]
35. TV6 and PDGFRB: a license to fuse.
Lierman E; Cools J
Haematologica; 2007 Feb; 92(2):145-7. PubMed ID: 17296561
[No Abstract] [Full Text] [Related]
36. ETV6 in hematopoiesis and leukemia predisposition.
Hock H; Shimamura A
Semin Hematol; 2017 Apr; 54(2):98-104. PubMed ID: 28637624
[TBL] [Abstract][Full Text] [Related]
37. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
38. Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome.
Kouides PA; Bennett JM
Am J Hematol; 1995 Jun; 49(2):157-62. PubMed ID: 7771469
[TBL] [Abstract][Full Text] [Related]
39. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
[TBL] [Abstract][Full Text] [Related]
40. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
